# An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

> **NCT06915727** · PHASE3 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 20 (estimated)

## Conditions studied

- Childhood Malignant Solid Neoplasm
- Childhood Malignant Thoracic Neoplasm
- Malignant Abdominal Neoplasm
- Malignant Neck Neoplasm
- Malignant Pelvic Neoplasm
- Metastatic Childhood Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Near Infrared Imaging
- **DRUG:** Pafolacianine Sodium
- **PROCEDURE:** Surgical Procedure

## Key facts

- **NCT ID:** NCT06915727
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06915727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06915727, "An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06915727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*